IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements (GRIPPER)
|Chronic Inflammatory Demyelinating Polyneuropathy||Drug: Intravenous Immunoglobulin|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER)|
- Daily grip strength (GS) measurements [ Time Frame: 6 months ]Extent of treatment related fluctuations to intravenous immunoglobulin (IVIg) in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) using a Jamar Dynamometer to capture daily grip strength (GS) measurements
- Percentage of IVIg treatment cycles in which the maximum and minimum grip strength (GS) measurements differ by more than 10% of the maximum [ Time Frame: 6 months ]Determine the percentage of IVIg treatment cycles in which the maximum and minimum grip strength (GS) measurements differ by more than 10% of the maximum and determine the percentage of subjects who have fluctuations of that magnitude.
- Rasch-built Overall Disability Scale [ Time Frame: 6 months ]Changes in Rasch-built Overall Disability Scale in the event a treating physician decides to modify IVIg therapy during study participation.
- Timed Up and Go test [ Time Frame: 6 months ]Changes in Timed up and Go test in the event a treating physician decides to modify IVIg therapy during study participation.
- Overall Neuropathy Limitations Scale [ Time Frame: 6 months ]Changes in Overall Neuropathy Limitations Scale in the event a treating physician decides to modify IVIg therapy during study participation.
- Health-Related Quality of Life (HRQOL) [ Time Frame: 6 months ]Changes in Health-Related Quality of Life (HRQOL) at three time points during the study (baseline, Week 12 and Week 24)
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2015|
|Estimated Study Completion Date:||May 2018|
|Estimated Primary Completion Date:||May 2018 (Final data collection date for primary outcome measure)|
Drug: Intravenous Immunoglobulin
Subjects will be recruited by individual site investigators. Prior to enrollment each potential subject will have their screening data reviewed by a panel of medical experts for confirmation of inclusion criteria. Each reviewer will be an independent, board-certified, practicing and experienced neurologist with a special interest in CIDP.
Enrolled subjects who have provided informed consent will be instructed to perform and document daily Jamar hand-held Dynamometer grip strength measurements in a paper diary for a 6 month time frame.
Weekly nursing visits will capture disability assessments, physical tests, adverse event and concomitant medications assessment, and other clinical changes that may affect grip strength measurements. Nurses will review each subjects captured grip data from paper diary on an iPad during weekly home assessments. Nurses will also administer the HRQOL Short-Form (SF) 36 questionnaire at the baseline, week 12 and week 24 study visits.
Serum immunoglobulin G (IgG) levels will be captured by the home study nurse at three time points surrounding IVIg infusions and will be classified as either trough, peak, or mid. Each subject will have serum Ig collected by blood draw for the first 4 IVIg treatment cycles, for a total of 12 blood draws per subject.
The "trough" serum IgG level will be collected immediately prior to Ig infusion. The "peak" serum IgG level will be collected 5 minutes post-Ig infusion. The "mid" serum IgG level will be collected two weeks post-Ig infusion.
There are currently no known biomarkers that can assist with CIDP diagnosis, prognosis, or treatment optimization. As part of this study, subjects will be required to have additional blood taken and stored for future use. Future use may include the possible discovery of specific biomarkers predicting the response to IVIg or other therapies, optimization of IVIg dosage based on pharmacodynamics, pathogenesis of CIDP, and more effective CIDP diagnostic markers. Blood taken for future use will be obtained with each serum IgG sample. No additional blood draws will be required.
Should IVIg therapy be discontinued during the study, daily grip strength measurements will continue to be performed and recorded in the subject diary for up to 30 days or to the end of the study, whichever comes first. Weekly nurse visits with collection of the disability assessments and serum IgG blood draws will continue for up to 4 home nurse visits or until the end of the study, whichever comes first.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02414490
|Contact: Timothy Walton, MHS, CCRP||877-342-9352 ext firstname.lastname@example.org|
|United States, Georgia|
|Neurology at John's Creek||Recruiting|
|Johns Creek, Georgia, United States, 30097|
|Contact: Albert Cook, MD 678-474-0151|
|Principal Investigator: Albert Cook, MD|
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Contact: Bart Jacher 312-695-8636 email@example.com|
|Principal Investigator: Senda Ajroud-Driss, MD|
|United States, Kansas|
|University of Kansas Medical Center||Recruiting|
|Kansas City, Kansas, United States, 66103|
|Contact: Laura Herbelin 913-588-5095 firstname.lastname@example.org|
|Principal Investigator: Mamatha Pasnoor, MD|
|United States, Minnesota|
|University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Sarah J Hilbert, MS, CCRP 612-624-7745 email@example.com|
|United States, New Hampshire|
|Dartmouth-Hitchcock Medical Center/Dartmouth Geisel School of Medicine||Recruiting|
|Lebanon, New Hampshire, United States, 03756|
|Contact: Charlotte A Jeffreys 603-650-3834 NeurologyResearch@hitchcock.org|
|Principal Investigator: Victoria H Lawson, MD|
|United States, New York|
|Columbia University Medical Center||Recruiting|
|New York, New York, United States, 10032|
|Contact: Allan Paras 212-305-6035 firstname.lastname@example.org|
|Principal Investigator: Thomas H Brannagan III, MD|
|United States, Virginia|
|University of Virginia||Recruiting|
|Charlottesville, Virginia, United States, 22903|
|Contact: Amruta Joshi, MS 434-982-0293 email@example.com|
|Principal Investigator: Ted Burns, MD|
|Principal Investigator:||Jeffrey A Allen, MD||University of Minnesota - Clinical and Translational Science Institute|